What are the clinical phases of dengue infection and how should each phase be managed?

Dengue Clinical Phases and Management

Dengue infection progresses through three distinct clinical phases—febrile, critical, and recovery—each requiring specific monitoring and management strategies, with the critical phase (typically days 3-7) being the most dangerous period when plasma leakage and shock can develop rapidly.

The Three Clinical Phases

1. Febrile Phase (Days 1-3 to 7)

Clinical Features:

• High-grade fever (often 39-40°C) with acute onset
• Severe headache with retro-orbital pain
• Myalgia and arthralgia (particularly back pain—"breakbone fever")
• Nausea and vomiting
• Skin flushing
• Maculopapular rash may appear late in this phase 1, 2

Management Approach:

• Hydration is paramount: Encourage oral fluids (water, oral rehydration solutions, fruit juices)
• Antipyretics: Paracetamol/acetaminophen only—avoid NSAIDs and aspirin due to bleeding risk
• Monitor daily: Complete blood count (CBC), hematocrit, platelet count
• Outpatient management is appropriate for most patients without warning signs
• Patient education about warning signs is critical 3, 4

Key Monitoring Parameters:

• Daily platelet count and hematocrit
• Fluid intake/output
• Warning signs (see below)

2. Critical Phase (Days 3-7, typically around defervescence)

This is the most dangerous period when plasma leakage occurs, typically coinciding with fever resolution 2, 5. Recent data shows the critical phase presents with distinct laboratory changes: significantly lower white blood cells, platelets, blood urea nitrogen, fibrinogen, and prothrombin time, but elevated liver enzymes (ALT, AST) and lactate dehydrogenase 5.

Warning Signs Requiring Hospitalization:

• Abdominal pain or tenderness
• Persistent vomiting
• Clinical fluid accumulation (ascites, pleural effusion)
• Mucosal bleeding
• Lethargy or restlessness
• Liver enlargement >2 cm
• Rising hematocrit with rapid platelet drop 6, 3

Fluid Resuscitation Strategy:

For patients with warning signs or plasma leakage:

• Crystalloids are first-line for initial resuscitation 7
• Start with isotonic crystalloids (normal saline or Ringer's lactate) at 5-7 mL/kg/hour for 1-2 hours
• Reassess clinically and adjust based on response
• Colloids may be beneficial in severe dengue shock syndrome (pulse pressure <10 mmHg), particularly in children 7
• In moderate shock (pulse pressure 10-20 mmHg), crystalloids and colloids show similar outcomes 7

Monitoring During Critical Phase:

• Hematocrit every 6-12 hours (rising hematocrit ≥20% indicates plasma leakage)
• Vital signs every 1-4 hours depending on severity
• Urine output (target >0.5 mL/kg/hour in adults, >1 mL/kg/hour in children)
• Assess for tissue perfusion: capillary refill, skin temperature, mental status 7

Severe Dengue/Dengue Shock Syndrome:

If tissue hypoperfusion persists despite aggressive fluid resuscitation:

• Use dopamine or epinephrine for fluid-resistant shock 7
• Preferentially infuse through central venous catheter; peripheral large-bore vein or intraosseous access acceptable if central access unavailable
• Monitor infusion site frequently for extravasation
• Consider hydrocortisone (up to 300 mg/day) or prednisolone (up to 75 mg/day) in adults requiring escalating vasopressor doses 7

3. Recovery Phase (Days 7-10+)

Clinical Features:

• Reabsorption of extravasated fluid
• Rash becomes prominent (present in 62.5% of recovery phase patients) 5
• Improvement in general well-being
• Appetite returns
• Bradycardia may occur
• Pruritus common 2, 5

Management:

• Avoid excessive fluid administration during this phase—risk of fluid overload as plasma leakage resolves
• Monitor for complications: fluid overload, congestive heart failure
• Gradual return to normal activity
• Follow-up CBC to document platelet recovery

Diagnostic Testing

Timing is critical for test selection:

• ≤7 days from symptom onset: PCR/NAAT on serum (gold standard for acute diagnosis) 1, 8
• ≥5-7 days from symptom onset: IgM capture ELISA 1, 8
• Convalescent confirmation: IgG ELISA at 3 weeks 1

Important caveat: Cross-reactivity with other flaviviruses (yellow fever, Japanese encephalitis, Zika) is well-recognized—obtain vaccination history for interpretation 1, 8

Platelet Transfusion

Prophylactic platelet transfusion is NOT recommended 3. Transfuse only for:

• Active significant bleeding with thrombocytopenia
• Invasive procedures with platelet count <50,000/mm³
• Severe thrombocytopenia (<10,000-20,000/mm³) with high bleeding risk

Critical Pitfalls to Avoid

1. Over-resuscitation during recovery phase: Can cause pulmonary edema and heart failure
2. NSAID use: Increases bleeding risk—use only paracetamol/acetaminophen
3. Premature discharge: Most deaths occur during critical phase when patients may feel better as fever resolves
4. Ignoring warning signs: These predict progression to severe dengue
5. Inadequate monitoring: Hematocrit and platelet trends are more important than absolute values

Special Populations

Pregnant women face increased risks including maternal death, hemorrhage, preeclampsia, and vertical transmission during peripartum period 8. Require closer monitoring and lower threshold for hospitalization.

Cardiac complications (myocarditis, arrhythmias, pericarditis) occur in 12-50% of hospitalized patients, with higher rates in pediatric populations and males 6. Any cardiac abnormality on echocardiography associates with adverse outcomes 6.

The evidence base for dengue management remains largely supportive as no specific antiviral therapy exists 3, 2. The cornerstone of reducing mortality is recognizing the critical phase early and providing judicious fluid resuscitation while avoiding both under- and over-resuscitation 7, 3.